Cure My Disease

Don't miss your cure!

 Log in / Sign up

Nerve-Block procedure tested against severe pancreatic and stomach cancer pain

NCT ID NCT07825870

Symptom relief Sponsor: Sahiwal medical college sahiwal Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 17, 2026 · Last updated Sep 18, 2026 · Updated 1 time

Summary

Researchers are studying whether a procedure called fluoroscopy-guided transdiscal splanchnic nerve neurolysis can safely reduce severe upper abdominal pain in adults with pancreatic, gastric, or hepatobiliary cancer. Participants first receive a diagnostic nerve block with local anesthetic; those who get at least 50% pain relief go on to have the nerve treated with alcohol or phenol under X-ray guidance. The study tracks pain scores, opioid use, functional status, quality of life, and complications over six months to see how well the approach works and how long relief lasts.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
chemical neurolysis of the splanchnic nerve using alcohol or phenol
What this could lead to
If it works, this could offer a way to ease severe cancer pain and lower reliance on opioid medicines for people with upper abdominal tumors.
What could go wrong
This is a small, single-center study with no comparison group, so results may not apply broadly. Nerve-block procedures can cause bleeding, infection, low blood pressure, or nerve injury, and pain relief may fade over time.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years. Confirmed diagnosis of pancreatic, gastric, or hepatobiliary malignancy with epigastric/upper abdominal pain. Baseline NRS ≥ 7 despite optimized pharmacotherapy, or intolerable opioid side effects. ≥ 50% pain relief on diagnostic splanchnic nerve block. Able to provide informed consent. Exclusion Criteria: * Coagulopathy (INR \> 1.5, platelets \< 50,000/µL). Local or systemic infection. Uncontrolled hypotension or severe cardiopulmonary compromise precluding prone positioning. Intestinal obstruction. Known allergy to contrast, local anesthetic, or the neurolytic agent. Patient refusal.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gastric cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Cancer Pain gastric cancer gastric neoplasm hepatobiliary neoplasm malignant pancreatic neoplasm pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gastric cancer Hepatobiliary cancer Pancreatic cancer Upper abdominal cancer pain

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Sahiwal Teaching Hospital

    Sahiwal, Punjab Province, 57000, Pakistan

More trials for these conditions

Other studies related to the condition(s) this trial covers.